A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 212 participants.

Also called NCT05659537

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 212 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05659537
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
India (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05659537. Allocation not applicable; no masking; primary purpose treatment. Start 2022-12-29 (actual); primary completion 2024-01-16 (actual). Results posted on 2025-02-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Dulaglutide
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05659537
Content hash
0dbfb13abe8d6d7110e1459c0a57dd18f2c14cb9426171f4ff4471908eb969d0